Evaluation
*
HighAbove AverageAverageBelow AverageLow
Anthony J. Olsznaski, MD, RPH
Brianna Hoffner, MS, ANP-BC, AOCNP
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Describe the mechanism of action for talimogne laherparepvec (T-VEC)
Describe how checkpoint inhibitors, both CTLA-4 and PD-L1, alter the body’s immune response to melanoma cells
Describe potential toxicities associated with checkpoint inhibitors, including etiology of these toxicities and management and/or prophylaxis
Explain how checkpoint inhibitors differ from other available treatment options for metastatic melanoma, including kinase inhibitors and cytotoxic chemotherapy
Discuss the role of the advanced practitioner as part of the collaborative practice team in caring for patients on immunotherapy treatments
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
This activity met my educational needs, expectations, and objectives
This activity was relevant to my practice
I feel confident treating patients in my practice based on this activity
This activity rates highly in comparison with other CE/CME activities in which I have participated in the last 12 months
The presentation was scientifically sound and free of commercial bias or influence
*
*
*
*
*